Item

Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

Ahmed, Syed Osman
; 
El Fakih, Riad
; 
Kharfan-Dabaja, Mohamed A.
; 
Syed, Farhatullah
; 
Mufti, Ghulam
; 
Chabannon, Christian
; 
Rondelli, Damiano
; 
Mohty, Mohamad
; 
Al Ahmari, Ali A.
; 
Gauthier, Jordan
... show 10 more
Author
Ahmed, Syed Osman
El Fakih, Riad
Kharfan-Dabaja, Mohamed A.
Syed, Farhatullah
Mufti, Ghulam
Chabannon, Christian
Rondelli, Damiano
Mohty, Mohamad
Al Ahmari, Ali A.
Gauthier, Jordan
Ruella, Marco
Perales, Miguel-Angel
Hashmi, Shahrukh
Alfraih, Feras
Ghorashian, Sarah
Alzahrani, Mohsen
Abba, Zubair
Koh, Mickey
Pasquini, Marcelo
Ruggeri, Annalisa
Garderet, Laurent
Albabtain, Abdulwahab
Weisdorf, Daniel
Greinix, Hildegard
Samarkandi, Hadeel
Hamad, Nada
Atsuta, Yoshiko
Hamadani, Mehdi
Hari, Parameswaran
Majhail, Navneet S.
Greco, Raffaella
Alzahrani, Hazzaa
Sureda, Anna
Yakoub-Agha, Ibrahim
Alahmari, Ali D.
Niederwieser, Dietger
Aljurf, Mahmoud
Supervisor
Department
Computer Vision
Embargo End Date
Type
Review
Date
2025
License
Language
English
Collections
Publications
Show all metadata
Research Projects
Organizational Units
Journal Issue
Abstract
Chimeric antigen receptor T cell (CAR-T) therapy is a genetically engineered cellular therapy that is currently integrated into the management of hematologic malignancies. Institutions treating patients with CAR-T therapy need to establish a framework of delivery that covers all the main components of the patient journey including intake of patients into the program from referring centers, patient selection according to established eligibility criteria, apheresis, logistics, bridging therapy, infusion, and postinfusion care. A CAR-T therapy program, with its unique requirements, needs to be delivered by a multidisciplinary team. Prior to the establishment of the program, a well-structured business plan should be developed with a clear financial and/or reimbursement model. Consideration should be given to overall capacity and staffing requirements. Standard operating procedures and guidelines are vital for ensuring that quality standards are clearly defined and adhered to. Institutions should develop a research plan for CAR-T therapy that may incorporate not only industry-sponsored trials, but also in-house manufacturing of investigational CAR-T products. This report presents recommendations from a group of international experts, highlighting the priorities and considerations when developing a new CAR-T program. © 2025 The American Society for Transplantation and Cellular Therapy
Citation
S. O. Ahmed et al., “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation,” Transplant Cell Ther, May 2025, doi: 10.1016/J.JTCT.2025.05.012
Source
Transplantation and Cellular Therapy
Conference
Keywords
CAR-T cell therapy, Chimeric antigen receptor, Program
Subjects
Source
Publisher
Elsevier
DOI
10.1016/j.jtct.2025.05.012
Additional links
https://www.sciencedirect.com/science/article/pii/S2666636725011960
Full-text link